All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-SLAMF7 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human SLAMF7. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD23 antibody linked to 4-1BB and CD3-zeta signaling domains.
CAR Construction : 7A8D5 -CD28-CD3ζ Fig.1 CS1 CAR-T cells specifically target CS1-positive target cells in vitro. S1-CD28-CAR-T cells were analyzed using an impedance-based cytotoxicity assay against CHO/Hela-CS1 stable cells with CHO/Hela as a negative control. Golubovskaya, V., Zhou, H., Li, F., Berahovich, R., Sun, J., Valentine, M., ... & Wu, L. (2021). Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma. Biomedicines, 9(10), 1422. |
CAR Construction : 7A8D5 -41BB-CD3ζ Fig.2 Determination of IFN-γ release. CS1-41BB-CD3 CAR-T cells secreted IFN-gamma with multiple myeloma MM1S cells. Golubovskaya, V., Zhou, H., Li, F., Berahovich, R., Sun, J., Valentine, M., ... & Wu, L. (2021). Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma. Biomedicines, 9(10), 1422. |
CAR Construction : 7A8D5 -41BB-CD3ζ Fig.3 Anti-tumor Activity of CAR-T cells. NSG mice were intravenously injected with MM1S multiple myeloma cells and treated with T cells or monospecific CS1, monospecific BCMA, or bispecific CS1-BCMA CAR-T cells. Golubovskaya, V., Zhou, H., Li, F., Berahovich, R., Sun, J., Valentine, M., ... & Wu, L. (2021). Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma. Biomedicines, 9(10), 1422. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-SLAMF7 (7A8D5) h(4-1BB-CD3ζ) CAR, pCDCAR1 (XS-0922-ZP1301). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION